

AMENDMENTS TO THE CLAIMS

1-55. **(Cancelled)**

56. **(Currently Amended)** A modified CTLA4-immunoglobulin fusion protein comprising a first peptide having at least one CTLA4 activity and a second peptide comprising a C γ 4 immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function, wherein said effector function is selected from the group consisting of: (a) a reduced ability to activate complement and (b) a reduced ability to bind to an Fc receptor, relative to an unmodified CTLA4-immunoglobulin fusion protein.

57. **(Previously Presented)** The modified CTLA4-immunoglobulin fusion protein of claim 56, wherein the first peptide comprises an extracellular domain of the CTLA4 protein.

58. **(Previously Presented)** The modified CTLA4-immunoglobulin fusion protein of claim 57, wherein the first peptide comprises amino acid residues 1-125 of the human CTLA4 protein.

59. **(Previously Presented)** The modified CTLA4-immunoglobulin fusion protein of claim 56, wherein the immunoglobulin constant region comprises a hinge region, a CH2 domain and a CH3 domain.

60. **(Cancelled)**

61. **(Previously Presented)** A CTLA4-immunoglobulin fusion protein, comprising a first peptide having at least one CTLA4 activity and a second peptide comprising an immunoglobulin constant region wherein the immunoglobulin constant region comprises the CH1 domain, hinge region, CH2 domain, and CH3 domain from a C γ 4 heavy chain.

62. **(Original)** The peptide of claim 61, wherein the immunoglobulin constant region is modified to reduce at least one constant region-mediated biological effector function.

63. **(Previously Presented)** The peptide of claim 61, wherein the first peptide has at least one CTLA4 activity and the hinge region of the second peptide includes at least one cysteine residue available for disulfide bond formation.

64. **(Cancelled)**

65. **(Previously Presented)** The CTLA4-immunoglobulin fusion protein of claim 59, wherein the CH2 domain is modified to reduce at least one biological effector function.

66. **(Cancelled)**

67. **(Previously Presented)** The CTLA4-immunoglobulin fusion protein of claim 66, wherein the CH2 domain is modified by substitution of an amino acid residue located at a position of an intact immunoglobulin heavy chain selected from the group consisting of position 234, position 235 and position 237.

68. **(Cancelled)**

69. **(Previously Presented)** The CTLA4-immunoglobulin fusion protein of claim 67 comprising the amino acid sequence shown in SEQ ID NO: 28.

70-91. **(Cancelled)**

92. **(Original)** The CTLA4-immunoglobulin protein of claim 69, wherein said fusion protein comprises a Leu to Glu substitution at position 235 and a Gly to Ala substitution at position 237.

93. **(Original)** The CTLA4-immunoglobulin protein of claim 61, wherein said fusion protein comprises a Leu to Glu substitution at position 235 and a Gly to Ala substitution at position 237.

94. **(Original)** The CTLA4-immunoglobulin protein of claim 67, wherein said fusion protein comprises a Leu to Glu substitution at position 235 and a Gly to Ala substitution at position 237.